Next-generation sequencing of a cohort of pulmonary large cell carcinomas reclassified by world health organization 2015 criteria

Archives of Pathology and Laboratory Medicine

Volumn 140, Issue 4, 2016, Pages 312-317

  Driver, Brandon R ^a   Portier, Bryce P ^a   Mody, Dina R ^a   Deavers, Michael ^a   Bernicker, Eric H ^a   Kim, Min P ^a   Teh, Bin S ^a   Santacruz, Jose F ^a   Kopas, Lisa ^a   Munden, Reginald F ^a,b   Cagle, Philip T ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; AGED; CLASSIFICATION; COHORT ANALYSIS; DNA SEQUENCE; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; LARGE CELL CARCINOMA; LUNG TUMOR; MALE; MIDDLE AGED; MUTATION; NON SMALL CELL LUNG CANCER; PATHOLOGY; PILOT STUDY; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; WORLD HEALTH ORGANIZATION;

ADENOCARCINOMA; AGED; BIOMARKERS, TUMOR; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PILOT PROJECTS; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53; WORLD HEALTH ORGANIZATION;

EID: 84964017427     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2015-0361-OA     Document Type: Article

References (17)

1. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology [published correction appears in Arch Pathol Lab Med. 2013;137(9):1174]. Arch Pathol Lab Med. 2013;137(6):828-860.
2. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-285.
3. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon, France: IARC Press; 2015. World Health Organization Classification of Tumours; vol 7.
4. Rekhtman N, Tafe LJ, Chaft JE, et al. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol. 2013;26(4):511-522.
5. Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med. 2013;5(209):209ra153.
6. Karlsson A, Brunnström H, Lindquist KE, et al. Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer [published online ahead of print June 17, 2015]. Oncotarget.
7. Cagle PT, Zhai QJ, Murphy L, Low PS. Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folate-linked therapeutic agents. Arch Pathol Lab Med. 2013;137(2):241-244.
8. Brown AF, Sirohi D, Fukuoka J, et al. Tissue-preserving antibody cocktails to differentiate primary squamous cell carcinoma, adenocarcinoma, and small cell carcinoma of lung. Arch Pathol Lab Med. 2013;137(9):1274-1281.
9. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248-249.
10. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS One. 2012;7(10):e46688.
11. Sholl LM. Large-cell carcinoma of the lung: a diagnostic category redefined by immunohistochemistry and genomics. Curr Opin Pulm Med. 2014;20(4):324-331.
12. Barbareschi M, Cantaloni C, Del Vescovo V, et al. Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. Am J Clin Pathol. 2011;136(5):773-782.
13. Hwang DH, Szeto DP, Perry AS, Bruce JL, Sholl LM. Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistin-guishable from solid-subtype adenocarcinoma. Arch Pathol Lab Med. 2014; 138(5):626-635.
14. Rossi G, Mengoli MC, Cavazza A, et al. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. Virchows Arch. 2014;464(1):61-68.
15. Tam IY, Leung EL, Tin VP, et al. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther. 2009;8(8):2142-2151.
16. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: Lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 2012; 18(4):1167-1176.
17. Schwaederle M, Elkin SK, Tomson BN, Carter JL, Kurzrock R. Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types. Cell Cycle. 2015;14(14):2355-2361.